Investment
Features
FeesSafety
Academy
More
Pluang+

Roundhill Magnificent Seven Covered Call ETF rated 'Sell' for poor performance and better alternatives exist.

Analyst Insights
24 Jul 2026
Seeking Alpha
View Source
Bearish
Roundhill Magnificent Seven Covered Call ETF rated 'Sell' for poor performance and better alternatives exist.

The Roundhill Magnificent Seven Covered Call ETF (MAGY) is rated 'Sell' due to its consistent underperformance compared to its underlying asset and peers. Despite high distribution rates, MAGY's active covered call strategy has delivered flat returns over the past year, while the underlying MAGS ETF gained 17%. Investors are advised to focus on total return and correlation rather than yield alone. Superior alternatives like YMAG offer better tracking and total returns for exposure to the Magnificent Seven covered call strategy.

More News

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...

Market News
Bullish
1 hour ago
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...

Market News
Bullish
2 hours ago
Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...

Company Fundamentals
Bullish
3 hours ago
Solana stablecoin reserves drop $1.12B in 16 days, signaling increased selling pressure and potential slippage risks.

Solana stablecoin reserves drop $1.12B in 16 days, signaling increased selling pressure and potential slippage risks.

Solana's stablecoin reserves fell from $17.45 billion on September 25 to $16.33 billion by October 11, a 6.4% decline indicating that $1.12 billion left the chain. This reduction reflects actual sell or transfer activity, not price changes, and sugge...

Market News
Bearish
4 hours ago
Strategy plans to keep buying Bitcoin after $176M STRC stock buyback, signaling ongoing BTC accumulation.

Strategy plans to keep buying Bitcoin after $176M STRC stock buyback, signaling ongoing BTC accumulation.

Strategy announced it repurchased $176 million of its STRC preferred stock while acquiring 334 BTC in Q3 2026, reporting a $21 billion gain on digital assets. Michael Saylor confirmed that Bitcoin purchases will continue, framing the STRC buyback as ...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App